Cyanamid Colony, Whyeth Residence Colony - Kritul (Atul)

 Upload a photo

1947

- The Company was incorporated on 20th September under the name
Lederle Laboratories (India) Ltd. as a private limited company. The
name was changed to Cyanamid India Ltd., on 31st October, 1962. It
became a full fledged public limited company in November 1965. The
Company Manufacture drugs, pharmaceuticals and agro-chemicals,
insecticides and animal health products. Initially, the Company was
a
wholly owned subsidiary of American Cyanamid Co., U.S.A.

1961

- A basic fermentation plant was built, for the manufacture, mainly
from indigenous raw materials, of the basic bulk drugs required for
the
formulations of the Lederle antibiotics, viz., Aureomycin,
Achromycin
and Ledermycin.

1962

- The Atul Products Ltd., Ahmedabad acquired by subscribing to a
fresh
issue of share, a 24% interest which was increased (also by
subscription to fresh issue of shares) to 35% in 1963.

1963

- The Agricultural division's malathion insecticide plant at Atul,
Valsad was commissioned. A wide range of pesticides as well as
animal
health products were introduced thereafter.

1964

- Since incorporation upto the end of the year, the Company issued
the
following shares:

- (i) 1,502 No. of Equity shares of Rs 100 each for cash at par to
American Cyanamid Co. U.S.A., in 1947,

- (ii) 15,160 No. of equity shares of Rs 100 each without payment in
cash to American Cyanamid Co., U.S.A., in 1953,

- (iii) 894 No. equity shares of Rs 100 each without payment in cash
to
American Cyanamid Co., U.S.A., in 1961,

- (iv) 10,329 No. of Equity shares of Rs 100 each at a premium of Rs
163.89 per shares to The Atul Products Ltd., during 1961 and 1962,

- (v) 997 No. of Equity shares of Rs 100 each without payment in
cash
to American Cyanamid Co., U.S.A., in 1962,

- (vi) 13,482 No. of Equity shares of Rs 100 each at a premium of Rs
55.80 per share to The Atul Products Ltd., and 12,884 No. of equity
shares of Rs 100 each without payment in cash to American Cyanamid
Co.,
U.S.A., in 1963 and

- (vii) 740 No. of Equity shares of Rs 100 each for cash in 1964.

1974

- 70,146 bonus shares issued on 18.3.1975 in prop. 1:1.

1979

- During June, the Company offered for sale 6,83,924 No. of Equity
shares (4,55,949 No. of Equity shares held by American Cyanamid Co.,
U.S.A. and 2,27,975 No. of Equity shares held by the Atul Products
Ltd.) Rs 10 each at a premium of Rs 12 per share to the resident
Indian
nationals. Out of these shares, 30,000 shares were reserved for
subscription by the employees of the Company and 6,53,924 shares
offered to the public. After the offer for sale, the
inter-connections
of the Company with The Atul Products Ltd., was severed under the
MRTP
Act.

- 3,15,657 bonus shares issued on 12.1.1979 in prop. 9:4. Shares
subdivided on 22.1.1979. Authorised capital increased effective
from
21.2.1979.

1981

- The products manufactured in organophosphate plant were THIMET,
ABATE and ACCOTHION.

1987

- During September-October, out of its holding of 25,07,721 No. of
equity shares in the Company, the American Cyanamid Co., U.S.A.,
offered to the resident Indian nationals 4,08,221 No. of Equity
shares
at a premium of Rs 20 per share to reduce its holding in the
Company.
These shares were offered as follows:

- (i) 2,60,304 shares to the existing resident Indian equity
shareholders excluding Gujarat Industrial and Investment Corporation
Ltd., and Ameer Trading Corporation Ltd.,

- (ii) 78,696 shares to the shareholders of Atul Products Ltd.,

- (iii) 50,000 shares to UTI and

- (iv) 19,221 shares to business associates of the Company.

- The Company issued 6,90,510 No. of equity shares at a premium of
Rs
20 per share to the resident Indian nationals simultaneously with
the
offer for sale of shares during September-October is as follows:

- (i) 2,18,443 shares to resident Indian equity shareholders
excluding
Gujarat Industrial & Investment Corporation Ltd., and Ameer Trading
Corporation Ltd.,

- (ii) 4,37,542 shares to shareholders of Atul Products Ltd., and

- (iii) 34,525 shares to employees (including Indian working
directors/workers of the Company. Thus along with the offer for
sale,
a total of 4,78,747 shares were offered as rights to the
shareholders
in proportion 7:10 besides offer to the other categories.

1988

- A new 45KL stainless steel fermentor was installed. A new
antibiotic
cynomycin and a pediatric suspension Penetrin were introduced.

- The Company obtained a licence for manufacture of two million
cynomycin capsules.

1989

- An industrial licence was received in February for the manufacture
of
150 tonnes of aeropromoter flocullants and collectors.

1990

- PROTON an effective herbicide was launched by the crop protection
chemicals division.

- Government approval was received for the manufacture of loxapine
(an
anti-psychotic agent).

1994

- The Agricultural products division launched Azodrin and Ripcord in
the agrochemical market. A new product by the name Tussivil (cough
syrup) was launched.

1996

- Approvals were received for the scheme for arrangement between
Cyanamid Agro Ltd. & Cyanamid India Ltd., and also for Wyeth
Laboratories Ltd., John Wyeth (India) Ltd. and Wyeth (India) Ltd in
the
Cyanamid India Ltd. The scheme became effective from September 12,
1997 and the Agro undertaking of the company was to be transferred
to
and vested in Cyanamid Agro Ltd. On amalgamation of Wyeth Companies
with the company, the name of the Company changed to Wyeth Lederle
Ltd.

1997

- Cyanamid India Limited, Cyanamid Agro Limited and the three Wyeth
companies are being amalgamated with a view to bifurcating their
business into two areas, agricultural products and pharmaceutical
products under two companies.

- The Scheme of Amalgamation will position Wyeth Lederle Limited as
the
tenth largest pharmaceutical company in India.

1998

- Wyeth Lederle India will be adding an anti-meningitis vaccine to
its
drugs portfolio. The vaccine, expected to be launched in a month,
will
combat HIB meningitis.

- The company launched a vaccine for meningitis which is witnessing
a
35 per cent plus growth rate.

1999

- Pharmaceutical major, Wyeth Lederle, is expanding its vaccines
business as the company is currently set to launch new vaccines in
India. The company had recently launched Pnu-Immune 23, a product
to
counters bacteria causing Pn.

- Pharma multinational Wyeth Lederle is exploring the possibility of
setting up a greenfield unit for manufacturing formulations.

- The Company has two manufacturing facilities in Valsad (Gujarat)
and
Ghatkopar (Maharashtra).

2000

- Wyeth Lederle and Cyanamid Agro are subsidiaries of the American
Home
Products Corporation.

- Wyeth has two manufacturing facilities in Pakistan.

- The Company is introducing `Premelle' and `Premelle Cycle', a
hormone
replacement therapy (HRT) in India.

- The Company has signed agreements with NSDL, CDSL and Tata
Consultancy Services, R&T agent, for dematerialisation of the
company's
equity shares.

- The Board has apppointed Mr. R.A. Shah as Director and Chairman,
Mr.
S. Kumaraswamy as Director.

- The Company to launch in the current year Zosyn, a hospital
antibiotic for severe infections, and an oncology product, which
increases the platelet count for patients under chemotherapy
treatment.

- Wyeth Lederle has launched Premelle and Premelle Cycle, pills
meant
for hormone replacement therapy.

2002

-The Wyeth Lederle agreed to amalgamate Geoffrey Manners & Co with
itself.

-Mr.A.W Khandekar has given his resignation as director of the
company.

-Wyeth Lederly Ltd has inaugurated its new manufacturing facility at
Verna, Goa.

-Changes in the Management of Wyeth Lederly:
1. Mr.Sunil Lalbhai appointed as Additional Director.
2. Mr.B J Poussot and Mr.H.F Bhabha ceased to be the director.
3. Mr.M H Bhabha appointed as Alternate to Mr.M M Larsen.

-Wyeth Lederly agreed to amalgamate Geoffrey Manners & Co. with
itself.

-Wyeth as set up high-tech solid dosage plant at Goa. The company has
shutdown
its formulations unit at Ghatkopar in Mumbai

-Wyethe Lederly has shifted its Registered Office to RBC, Mahindra
Towers, 4thfloor
A Wing , De G M Bhosale Road, Worli, Mumbai - 400 018.

-Wyeth Lederly has obtained the environment ministry's approval to
market its
genetically modified drug Mylotarg, for treating relapse cases of CD
33 positive
acute myeloid Leukamia.

2007

- Wyeth Ltd has informed that the Board of Directors of the Company
at its meeting held on October 27, 2007, has appointed Mr. Ashish
Dalal, as an Additional Director. Mr. Ashish Dalal is a Non-Executive
Independent Director.